Entrada Therapeutics (TRDA) Return on Equity (2021 - 2026)

Entrada Therapeutics' Return on Equity history runs 6 years deep, the most recent figure standing at 0.01% for Q1 2026.

• In Q1 2026, Return on Equity fell 1.0% year-over-year to 0.01%; the TTM figure through Mar 2026 stood at 0.01% (down 1.0% YoY), while the FY2025 annual figure was 0.0%, down 1.0% from the prior year.
• Return on Equity was 0.01% for Q1 2026 at Entrada Therapeutics, down from 0.0% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.0% in Q2 2024 to a low of 0.01% in Q1 2026.
• Historically, Return on Equity has averaged 0.0% across 5 years, with a median of 0.0% in 2022.
• The sharpest annual moves came in 2022 and 2024: Return on Equity slipped 1 bps in 2022, then gained 1 bps in 2024.
• A 5-year view of Return on Equity shows it stood at 0.0% in 2022, then jumped by 94 bps to 0.0% in 2023, then soared by 671 bps to 0.0% in 2024, then plunged by 389 bps to 0.0% in 2025, then dropped by 30 bps to 0.01% in 2026.
• The last three Return on Equity figures came in at 0.01% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.